Physician profile
Gary Fishman
NPI 1558303354
$3,383.20
in general payments reported to CMS, 2019-2025
19 companies · $737 in 2025
The $737 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $693 · 2020: $187 · 2021: $446 · 2022: $427 · 2023: $279 · 2024: $615 · 2025: $737.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,630.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,629.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,009.61 | 2019-2025 | Clareon Panoptix Pro, Simbrinza, Clareon |
| Oyster Point Pharma, INC. | $341.56 | 2022-2025 | Tyrvaya |
| Abbvie INC. | $297.42 | 2022-2024 | |
| Biotissue Holdings INC. | $285.72 | 2024 | |
| Novartis Pharmaceuticals Corporation | $252.66 | 2019-2023 | |
| Bausch & Lomb Americas INC. | $210.96 | 2024-2025 | Miebo, Vyzulta |
| Aerie Pharmaceuticals, INC. | $201.50 | 2019-2021 | |
| Eyevance Pharmaceuticals LLC | $134.89 | 2020-2022 | |
| Ivantis, INC | $128.72 | 2021 | |
| Sight Sciences, INC. | $89.59 | 2019 | |
| Dompe US, INC. | $83.55 | 2024-2025 | Oxervate |
| Johnson & Johnson Surgical Vision, INC. | $79.06 | 2019 | |
| Allergan, INC. | $75.23 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $56.69 | 2019-2020 | |
| Shire North American Group INC | $39.74 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $30.03 | 2025 | Xdemvy |
| Glaxosmithkline, LLC. | $29.94 | 2020-2023 | Nucala |
| Horizon Therapeutics Plc | $20.76 | 2022 | |
| Harrow Eye, LLC | $15.57 | 2025 | Vevye |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Fishman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.